Purpose: To evaluate the effect of vitreomacular traction (VMT) on the visual acuity outcomes and central retinal thickness measurements following intravitreal antivascular endothelial growth factor (anti-VEGF) therapy for the treatment of exudative AMD.
group between baseline and 12 months showed no significant difference (P=0.67), while the PrONTO study and control group showed a highly significant difference at 12 months compared to baseline (P< 0.001). Mean CRT values at 6 and 12 months were essentially at baseline levels (0.26 um, -0.62 um respectively).
Conclusion: VMT at baseline, existing concurrently with newly diagnosed exudative AMD treated with intravitreal anti-VEGF therapy on a variable dosing regime, was associated with poorer visual outcomes and a decreased response to reduction in CRT, compared to a control group of wet AMD without VMT treated with intravitreal anti-VEGF and compared to major variable dosing studies for intravitreal anti-VEGF in exudative AMD.
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Amendments:
I have added the Snellen equivalents to the ETDRS visual acuities in Table 1 as  requested above. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 Summary statement:
In patients with AMD treated with anti-VEGF therapy on a variable dosing regime, concurrent vitreomacular traction was associated with a less favourable visual outcome and less of a reduction in central retinal thickness compared to a control group of treated wet AMD without VMT and compared to the major variable dosing regime studies of exudative AMD treated with anti-VEGF therapy 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 Results: BCVA results showed a visual acuity improvement that peaked at 3 months with 2.47 letters, well below other variable dosing studies for anti-VEGF therapy in exudative AMD. This was then followed by a steady decline with mean BCVA at 12 months ending below the baseline level (-1.00 letters) compared to a gain of 9.39 letters in the control group at 12 months.
Comparison of the mean CRT in the VMT group between baseline and 12 months showed no significant difference (P=0.67), while the PrONTO study and control group showed a highly significant difference at 12 months Although the exact pathogenesis of AMD remains unclear it is known that the CNV lesion predominantly affects the outer retina and retinal pigment epithelium (RPE), and that genetic factors can influence its development and response to treatment [10] [11] [12] [13] It is possible that the vitreous contributes to the initial pathogenesis or progression of AMD as a number of studies show a higher incidence of posterior vitreous attachment in AMD (both for exudative and non-exudative AMD eyes) compared to age-matched control eyes. Small studies suggest that patients with wet AMD and concurrent VMA may not respond as expected to anti-VEGF therapy. 9, 15, 16 This reduced response to treatment has been attributed to chronic tractional mechanical forces or induced inflammation from the traction. [7] [8] [9] 16 Another study has looked at VMA in association with CNV and polypoidal choroidal vasculopathy (PCV) and did not find a difference in visual outcomes. 17 Filloy et al 18 in a European study, compared the responses to ranibizumab for wet AMD with VMT (n=18) with a control group of ranibizumab for wet AMD without VMT and found that patients with accompanying VMT showed a tendency to have poorer visual outcomes. In addition, a higher number of intravitreal injections were required in the VMT group compared to the control group.
The purpose of this study is to assess the treatment responses to anti-VEGF therapy in wet AMD eyes with co-existing VMT pathology in a larger consecutive series. We assessed the outcomes of patients with VMT associated with CNV (secondary to AMD) treated with anti-VEGF therapy employing a variable dosing or pro re nata (PRN) regime. We compared the outcomes of these wet AMD patients with co-existent VMT treated with PRN anti-VEGF therapy to a control group without VMT on OCT treated with anti-VEGF therapy in the same eye unit as the VMT patients with the same PRN dosing regime. We also compared to the standard outcomes of wet AMD patients treated with similar PRN dosing regimes in large published studies .   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 Inclusion criteria used for the study were: VMT was identified on tomographic scans as per the definition above.
Patients with VMA only were not included in the study.
We compared the visual acuity outcomes and central retinal thickness (CRT) measurements of patients with exudative AMD associated with VMT with data from our control group of patients from CATT 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 Statistical analysis, comparisons and graphs were performed using GraphPad Prism software version 6.0 (Mac OS X, GraphPad Software, La Jolla California USA, www.graphpad.com). Follow-up and baseline CRT in our study were compared using the paired student t test. P<0.05 was considered statistically significant.
Results
The comparison between our study population with CNV secondary to AMD associated with VMT (UK VMT PRN), our control group of CNV secondary to AMD without VMT and the other studies is shown in table 1.   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 BCVA results showed that there was a visual acuity improvement peaking at 3 months of 2.47 letters followed by a steady decline. Mean visual acuity at 12 months ended below the baseline level (Figure 1) , whereas in the control group the mean improvement in visual acuity peaks at 12 months with a mean gain of 9.39 letters (Figure 2 ).
Results were then compared against data from CATT ) respectively. Figure 3 shows a comparison of our study group (UK VMT PRN) with our control group and with the other studies mentioned, clearly illustrating the difference in treatment response and overall poor outcome at the end of the 12-month period. 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 Comparison of the mean CRT in the VMT group between baseline and 12 months showed no significant difference (P=0.67), while the control group (figure 4) and the PrONTO 20 study group showed a highly significant difference at 12 months compared to baseline (P< 0.001). Figure 5 illustrates that the VMT group data shows a slight reduction in CRT at 3 months but
average CRT values at 6 and 12 months revert back to near baseline levels.
Discussion
This study of wet AMD patients having concurrent vitreomacular traction (VMT) being treated with anti-VEGF therapy showed a poorer visual outcome in these patients including a marked difference compared to a control group without VMT on OCT treated with ranibizumab for CNV in AMD with the same PRN dosing regime. The central retinal thickness (CRT) showed no significant reduction when compared to baseline at 12 months. The poorer visual outcome was noted at all time points studied with the greatest difference at the 12-month point when the average visual acuity was below the baseline level in the VMT group. This was mirrored by less of a reduction in mean CRT with anti-VEGF therapy with a small reduction in mean CRT at 3 months only followed by a return of the mean CRT at 6 and 12 months essentially back to baseline. There was no significant change at 12 months compared to baseline in the VMT group compared to a statistically significant reduction in CRT at 12 months in the control group and the PrONTO 20 study.
A number of studies have postulated that vitreous traction can have a deleterious effect on the treatment response of anti-VEGF therapy for wet 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 AMD. [7] [8] 16 It has also been suggested that the presence of VMT can be correlated with the severity of wet AMD 16 . Theories linking VMT and the poorer response to anti-VEGF treatment in this group include chronic inflammation and mechanical tractional forces as discussed previously. Some reports have identified an abnormally strong attachment at the macula in patients with wet AMD. 23 It has also been shown that vitrectomy to detach the posterior vitreous cortex could improve CNV regression. 24 In 2 In contrast to other variable-dosing regime studies showing better outcomes, the presence of VMT often leads to poorer visual and anatomical outcomes during anti-VEGF therapy for wet AMD. Surgical intervention to address VMT is an option to be considered in managing this difficult group of patients when the expected response is not achieved. The successful use of pharmacologic vitreolysis 26, 27 to relieve symptomatic vitreomacular traction 28, 29 is an   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 interesting development that may also have uses in this group of patients and studies exploring this are underway. It is important to address the patient's expectations and perform adequate counselling prior to commencing treatment to inform this group of patients that the prognosis in cases of VMT associated with wet AMD treated with anti-VEGF treatment alone is likely to be less favourable. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 Figure Legends 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 Fig 1, Fig 2, etc. ): figure 3 updated with controls. F Figure 4 Click here to download Figure ( Please type in the figure number in the Description Box; Fig 1, Fig 2, etc. 
